#London #United Kingdom #oncology #Nuvation Bio #Jefferies Conference

Nuvation Bio at the Jefferies Global Healthcare Conference

Nuvation Bio, a global leader in oncology dedicated to addressing significant challenges in cancer treatment, is set to present at the upcoming Jefferies Global Healthcare Conference in London. This distinguished event will take place on November 17, 2026, featuring a fireside chat with Nuvation Bio's Founder and CEO, Dr. David Hung, alongside Philippe Sauvage, the company's Chief Financial Officer. The session is scheduled to commence at 2:30 p.m. GMT and is poised to provide valuable insights into the company's innovations and future direction in the field of oncology.

Key Highlights of the Presentation

During the presentation, the executives are expected to share key updates regarding Nuvation Bio's innovative pipeline and strategic goals aimed at transforming cancer care. As an organization at the forefront of developing next-generation therapies, Nuvation Bio is applying its resources towards groundbreaking treatments designed to improve patient outcomes.

Some notable projects currently in their pipeline include taletrectinib (IBTROZI®), known for its efficacy as a ROS1 inhibitor, with a focus on targeting specific patient needs. Other exciting developments include safusidenib, recognized for its ability to penetrate the brain as an IDH1 inhibitor, and an advanced drug-drug conjugate (DDC) program that stands to change the landscape of cancer therapy.

Webcast Availability

For those unable to attend, the conversation will be accessible via a live webcast on Nuvation Bio's Investor Relations page. Following the live event, an archived recording will remain available for 90 days, ensuring that stakeholders can stay informed about the company’s ongoing initiatives.

About Nuvation Bio

Founded in 2018, Nuvation Bio is helmed by Dr. David Hung, a prominent figure in the biopharmaceutical sector, previously known for establishing Medivation, which delivered one of the most prominent treatments for prostate cancer on the market. With headquarters in New York, and regional offices in San Francisco, Boston, and Shanghai, Nuvation Bio bolsters its mission to reshape patient care through advanced oncology solutions.

As a significant player in the pharmaceutical landscape, Nuvation Bio consistently strives to not only innovate but also to create profound impacts on patients' lives. The upcoming presentation at the Jefferies Global Healthcare Conference reaffirms their commitment to transparency and collaboration within the healthcare community.

Stay Connected

For further updates, visit Nuvation Bio's website or follow them on social media platforms like LinkedIn and X (@nuvationbioinc). This presentation will be an essential stop for investors, healthcare professionals, and anyone interested in the future of oncology treatment.